HRP20130906T1 - Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze - Google Patents

Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze Download PDF

Info

Publication number
HRP20130906T1
HRP20130906T1 HRP20130906AT HRP20130906T HRP20130906T1 HR P20130906 T1 HRP20130906 T1 HR P20130906T1 HR P20130906A T HRP20130906A T HR P20130906AT HR P20130906 T HRP20130906 T HR P20130906T HR P20130906 T1 HRP20130906 T1 HR P20130906T1
Authority
HR
Croatia
Prior art keywords
compound
formula
solvent
salt
cinchonidine
Prior art date
Application number
HRP20130906AT
Other languages
English (en)
Croatian (hr)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel DEPRÉ
Véronique CERPENTIER
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of HRP20130906T1 publication Critical patent/HRP20130906T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20130906AT 2008-12-23 2009-12-22 Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze HRP20130906T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
PCT/EP2009/067715 WO2010072742A1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
HRP20130906T1 true HRP20130906T1 (hr) 2013-10-25

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130906AT HRP20130906T1 (hr) 2008-12-23 2009-12-22 Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze

Country Status (22)

Country Link
US (2) US8927722B2 (enExample)
EP (1) EP2382198B1 (enExample)
JP (1) JP5687631B2 (enExample)
KR (1) KR101734507B1 (enExample)
CN (1) CN102264715B (enExample)
AR (1) AR074863A1 (enExample)
AU (1) AU2009331530B2 (enExample)
BR (1) BRPI0923393B1 (enExample)
CA (1) CA2745565C (enExample)
CY (1) CY1114488T1 (enExample)
DK (1) DK2382198T3 (enExample)
ES (1) ES2429013T3 (enExample)
HR (1) HRP20130906T1 (enExample)
IL (1) IL213246A (enExample)
MX (1) MX2011006764A (enExample)
PL (1) PL2382198T3 (enExample)
PT (1) PT2382198E (enExample)
RU (1) RU2016120007A (enExample)
SI (1) SI2382198T1 (enExample)
SM (1) SMT201300116B (enExample)
TW (1) TWI461424B (enExample)
WO (1) WO2010072742A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease
TWI565704B (zh) 2011-09-22 2017-01-11 健生醫藥公司 用於製備hcv巨環蛋白酶抑制劑之方法及中間物
JP6231482B2 (ja) 2011-10-28 2017-11-15 ヤンセン ファーマシューティカルズ,インコーポレーテッド 大環状プロテアーゼ阻害剤tmc435の中間体の改善された製造方法
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
IN2014MN02652A (enExample) 2012-06-08 2015-08-21 Gilead Sciences Inc
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
SI2859009T1 (sl) * 2012-06-08 2017-12-29 Gilead Sciences, Inc. Makrociklični inhibitorji flaviviridae virusov
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ, インコーポレイテッド C型肝炎ウイルスの大環状二環式阻害剤
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
CN101146806A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
EP1919904B1 (en) * 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2483067C2 (ru) * 2007-02-01 2013-05-27 Тиботек Фармасьютикалз Лтд. Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с
MX2009008541A (es) * 2007-02-08 2009-08-18 Tibotec Pharm Ltd Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease

Also Published As

Publication number Publication date
KR20110099048A (ko) 2011-09-05
MX2011006764A (es) 2011-08-03
CA2745565C (en) 2017-03-07
US20110257403A1 (en) 2011-10-20
EP2382198A1 (en) 2011-11-02
DK2382198T3 (da) 2013-09-30
CN102264715A (zh) 2011-11-30
TW201033205A (en) 2010-09-16
RU2016120007A (ru) 2018-11-13
SI2382198T1 (sl) 2013-11-29
JP2012513381A (ja) 2012-06-14
BRPI0923393B1 (pt) 2018-06-19
IL213246A0 (en) 2011-07-31
US20150080577A1 (en) 2015-03-19
BRPI0923393A2 (pt) 2015-07-28
PL2382198T3 (pl) 2013-11-29
AU2009331530B2 (en) 2015-04-09
AU2009331530A1 (en) 2011-06-23
SMT201300116B (it) 2013-11-08
US8927722B2 (en) 2015-01-06
PT2382198E (pt) 2013-10-01
WO2010072742A1 (en) 2010-07-01
EP2382198B1 (en) 2013-07-10
AR074863A1 (es) 2011-02-16
CA2745565A1 (en) 2010-07-01
CN102264715B (zh) 2015-12-02
CY1114488T1 (el) 2016-10-05
KR101734507B1 (ko) 2017-05-11
HK1164839A1 (zh) 2012-09-28
ES2429013T3 (es) 2013-11-12
IL213246A (en) 2017-10-31
JP5687631B2 (ja) 2015-03-18
RU2011130895A (ru) 2013-01-27
TWI461424B (zh) 2014-11-21
US9115077B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
RU2016120007A (ru) Способы и промежуточные соединения для получения макроциклического ингибитора протеазы вируса гепатита c
JP2012513381A5 (enExample)
KR101598135B1 (ko) Hcv의 마크로사이클릭 프로테아제 억제제의 제조 방법 및 중간체
ES2291465T3 (es) Procedimiento para preparar oxazolidinonas.
RU2742005C2 (ru) Способы получения 4-алкокси-3-(ацил или алкил)оксипиколинамидов
US20240124481A1 (en) New compounds and methods of their manufacturing
CN107353222A (zh) 制备2‑氨基‑n‑(2,2,2‑三氟乙基)乙酰胺的方法
KR20160138538A (ko) 소듐 (2s, 5r)-6-(벤질옥시)-7-옥소-1,6-다이아자바이사이클로[3.2.1]옥테인-2-카복실레이트의 제조 방법
ES2991258T3 (es) Procedimientos y productos intermedios para producir compuestos de diazaespiro-lactama
Liu et al. A facile solid phase synthesis of tetramic acid
JP2021515018A (ja) 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法
TWI924296B (zh) 製備(s)-3-羥基-1-(1h-吲哚-5-基)-2-側氧吡咯烷-3-羧酸3,5-二氟-苯甲醯胺之方法
JP6235473B2 (ja) 大環状hcvプロテアーゼ阻害剤を製造するための方法および中間体
CN106749515A (zh) 一种匹多莫德的合成方法
CN104910068A (zh) 一种2-氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法
WO2016046843A1 (en) Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
KR20250017014A (ko) 에독사반 및 이의 토실산염 1수화물의 신규 제조방법
RU2742765C1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
ES2296806T3 (es) Nuevos derivados de cianoril (o cianoheteroaril)-carbonil-piperazini l-pirimidinas, su preparacion y su aplicacion como medeicamentos.
RU2794754C1 (ru) Способ получения (1r,2s,5s)-n-[(1s)-1-циано-2-[(3s)-2-оксопирролидин-3-ил]этил]-3-[(2s)-3,3-диметил-2-[(2,2,2-трифторацетил)амино]бутаноил]-6,6-диметил-3-азабицикло[3.1.0]гексан-2-карбоксамида
KR20190129863A (ko) 케톨라이드 화합물의 제조 방법
JP2026508515A (ja) Cav3.2-usp5相互作用を阻害するためのテトラヒドロキノリン誘導体
WO2023200364A1 (ru) Способы получения (1r,2s,5s)-n-[(1s)-1-циано-2-[(3s)-2-оксопирролидин-3-ил]этил]-3-[(2s)-3,3-диметил-2-[(2,2,2-трифторацетил)амино]бутаноил]-6,6-диметил-3-азабицикло[3.1.0]гексан-2-карбоксамида
CN103288761B (zh) 一种合成1,2,3,4‑喹唑啉‑2,4‑二酮衍生物的新方法
CN121426800A (zh) 一种2-氨基-5-溴咪唑并[1,2-a]吡啶的制备方法